However, the antitumor effect exerted by the combination of ATR inhibitor with topoisomerase (TOP1) inhibitor and the subsequent mechanisms underlying enhanced tumor immunogenicity in SCLC remain poorly understood. Here, TOP1 is linked to neoplasm.